All News Purple Biotech Ltd

Equities

PPBT

IL0007650166

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 08:49:56 2024-05-19 am EDT			5-day change	1st Jan Change
18.2 ^ILa	+2.25%		-6.19%	-42.95%

Apr. 25	Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	CI
Mar. 14	Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	Apr. 25	CI
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024	Mar. 28	AQ
Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology	Mar. 14	CI
Purple Biotech : Immediate Report	Mar. 06	PU
6K:Fourth Quarter and Full-Year 2023 Financial Results	Mar. 05	PU
Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results	Mar. 05	AQ
Purple Biotech Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 05	CI
Purple Biotech Presents Data of Its Phase 1 Head & Neck Cancer of NT219 in Combination with Cetuximab At ESMO TAT Congress 2024	Feb. 27	CI
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024	Feb. 27	AQ
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial	Feb. 13	AQ
Purple Biotech Reaches Recommended Phase 2 Dose for NT219	Feb. 01	CI
Purple Biotech Ltd. Announces Executive Changes	Dec. 20	CI
Purple Biotech Ltd. Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	Dec. 14	CI
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	Dec. 14	AQ
Papillary Thyroid Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 30	AQ
Purple Biotech Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 21	CI
Purple Biotech Reports Third Quarter 2023 Financial Results	Nov. 21	AQ
Purple Biotech Fortifies NT219 Patent Protection	Nov. 02	AQ
Purple Biotech : Other Report or Announcement	23-10-31	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Purple Biotech Ltd

Equities

PPBT

IL0007650166

All News

Filters